ERBB2 and breast cancer: IFN-γ has the potential to mediate degradation of HER2 through a ubiquitin proteasomal pathway in HER2pos BC cells.25 IFN-γ in combination with anti-HER2 antibodies, trastuzumab and pertuzumab, has been shown to increase senescence and apoptosis via STAT1 signaling activation in HER2pos BC cells.28 This study provides confirmative evidence for the previous finding that enhanced STAT1 activation was observed following HER2-DC1 i.t. combined with anti-HER2 antibodies treatment in a HER2pos BC model.